Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Nephrol ; 56(3): 241-6, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11597040

ABSTRACT

A case of Tsukamurella peritonitis associated with peritoneal dialysis in a 23-year-old woman is described. The organism was difficult to identify and was mistaken for Corynebacterium and atypical mycobacteria. Despite prolonged, multidrug, antimicrobial therapy with conventional antibiotics including vancomycin, ciprofloxacin, rifampin, gentamicin and ceftazidime, catheter removal was required to successfully treat peritonitis. Human infection due to this organism is rare and has been previously reported in only 13 cases, 1 of which was peritonitis. We describe here the second case of Tsukamurella peritonitis associated with peritoneal dialysis.


Subject(s)
Actinomycetales Infections/etiology , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Peritonitis/etiology , Actinomycetales/drug effects , Actinomycetales Infections/diagnosis , Actinomycetales Infections/drug therapy , Adult , Female , Humans , Microbial Sensitivity Tests , Peritonitis/diagnosis , Peritonitis/drug therapy , Peritonitis/microbiology
2.
Nephron ; 89(3): 337-9, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11598399

ABSTRACT

An elderly, nondiabetic, chronic hemodialysis patient is described here who had profound hypoglycemia for a myriad of reasons including renal failure, malnutrition, and quinine use. Furthermore, by biochemical parameters the patient had hyperinsulinemia, which was consistent with the diagnosis of an insulinoma. However, a tumor was not identified by noninvasive radiologic imaging as is often the case and the patient was not a candidate for surgical exploration. Diazoxide at a dose of 225 mg/day was used to successfully manage this patient's hypoglycemia. Previous experience with the use of diazoxide for hyperinsulinism in the hemodialysis population is limited and this case is the second report of its use for this purpose.


Subject(s)
Diazoxide/therapeutic use , Hyperinsulinism/drug therapy , Aged , Aged, 80 and over , Humans , Hyperinsulinism/etiology , Hypoglycemia/etiology , Insulinoma/complications , Nutrition Disorders/complications , Pancreatic Neoplasms/complications , Renal Dialysis
3.
Kidney Int ; 59(2): 710-7, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11168953

ABSTRACT

BACKGROUND: Gitelman's syndrome (GS), also called Gitelman's variant of Bartter's syndrome, is an autosomal recessive renal disorder characterized by hypokalemia, hypomagnesemia, metabolic alkalosis, and hypocalciuria. GS is caused by inactivating mutations in the thiazide-sensitive sodium chloride cotransporter gene (NCCT). It is also known as the "milder" form of Bartter's syndrome, as patients with GS are usually diagnosed in adulthood during routine investigation. Symptoms reported in the literature range from asymptomatic, to mild symptoms of cramps and fatigue, to severe manifestations such as tetany, paralysis, and rhabdomyolysis. This is the first systematic evaluation of a large group of patients with genetically defined GS. METHODS: We evaluated the symptoms and quality of life (QOL) in 50 adult GS patients with confirmed mutations in NCCT, using a standardized questionnaire. This cohort was compared with 25 age- and sex-matched controls. RESULTS: GS patients were significantly more symptomatic than controls. The most common symptoms were salt craving, with musculoskeletal symptoms such as cramps, muscle weakness, and aches and constitutional symptoms such as fatigue, generalized weakness and dizziness, and nocturia and polydipsia. Forty-five percent of GS patients consider their symptoms a moderate to big problem. Measures of health-related QOL were significantly lower in GS patients compared with controls, particularly in terms of role limitations caused by physical health, emotion, level of energy, and general health perception. CONCLUSIONS: This descriptive study indicates that GS is not an asymptomatic disease and adversely affects QOL in these patients. Further studies are needed to assess the impact of therapy on symptoms and QOL.


Subject(s)
Bartter Syndrome/physiopathology , Health Status , Quality of Life , Adolescent , Adult , Aged , Bartter Syndrome/complications , Female , Humans , Kidney Diseases/etiology , Male , Middle Aged , Musculoskeletal Diseases/etiology
4.
Am J Med Sci ; 322(6): 316-32, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11780689

ABSTRACT

Inherited hypokalemic metabolic alkalosis, or Bartter syndrome, comprises several closely related disorders of renal tubular electrolyte transport. Recent advances in the field of molecular genetics have demonstrated that there are four genetically distinct abnormalities, which result from mutations in renal electrolyte transporters and channels. Neonatal Bartter syndrome affects neonates and is characterized by polyhydramnios, premature delivery, severe electrolyte derangements, growth retardation, and hypercalciuria leading to nephrocalcinosis. It may be caused by a mutation in the gene encoding the Na-K-2Cl cotransporter (NKCC2) or the outwardly rectifying potassium channel (ROMK), a regulator of NKCC2. Classic Bartter syndrome is due to a mutation in the gene encoding the chloride channel (CLCNKB), also a regulator of NKCC2, and typically presents in infancy or early childhood with failure to thrive. Nephrocalcinosis is typically absent despite hypercalciuria. The hypocalciuric, hypomagnesemic variant of Bartter syndrome (Gitelman syndrome), presents in early adulthood with predominantly musculoskeletal symptoms and is due to mutations in the gene encoding the Na-Cl cotransporter (NCCT). Even though our understanding of these disorders has been greatly advanced by these discoveries, the pathophysiology remains to be completely defined. Genotype-phenotype correlations among the four disorders are quite variable and continue to be studied. A comprehensive review of Bartter and Gitelman syndromes will be provided here.


Subject(s)
Alkalosis/genetics , Bartter Syndrome/genetics , Hypokalemia/genetics , Potassium Channels, Inwardly Rectifying , Receptors, Drug , Renal Tubular Transport, Inborn Errors/genetics , Symporters , Alkalosis/classification , Alkalosis/etiology , Bartter Syndrome/classification , Bartter Syndrome/etiology , Carrier Proteins , Humans , Hypokalemia/classification , Hypokalemia/etiology , Infant , Infant, Newborn , Potassium Channels/genetics , Renal Tubular Transport, Inborn Errors/classification , Renal Tubular Transport, Inborn Errors/etiology , Sodium Chloride Symporters , Sodium-Potassium-Chloride Symporters/genetics , Solute Carrier Family 12, Member 1 , Solute Carrier Family 12, Member 3 , Syndrome
5.
Am J Nephrol ; 20(4): 332-8, 2000.
Article in English | MEDLINE | ID: mdl-10970989

ABSTRACT

Type B lactic acidosis, a rare but often fatal disorder, has been reported in 21 AIDS patients on antiretroviral therapy (ART). We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine. The lactic acidosis occurred in the absence of mitochondrial myopathy, hepatomegaly, or liver failure. This is the second report of lactic acidosis in a patient on stavudine and lamivudine. This patient recovered after aggressive supportive therapy including intravenous alkali and fluid administration as well as continuous venovenous hemodiafiltration. A single dose of dichloroacetate (DCA) was associated with a decrease in the serum lactate level by 20%, which persisted for more than 24 h. Seventeen months after recovery, the patient was rechallenged with ART without recurrence of lactic acidosis. We review and summarize all reported cases of patients with ART-associated lactic acidosis reported in the English literature.


Subject(s)
Acidosis, Lactic/chemically induced , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/adverse effects , Acidosis, Lactic/blood , Acidosis, Lactic/drug therapy , Adult , Anti-HIV Agents/therapeutic use , Dichloroacetic Acid/therapeutic use , Female , Humans , Lactic Acid/blood , Lamivudine/adverse effects , Lamivudine/therapeutic use , Stavudine/adverse effects , Stavudine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...